CD38 and Miyoshi myopathy: Thus, we performed a meta-analysis to indirectly compare the effect and safety of the MAbs targeting CD38, SLAMF7, and PD-1/PD-L1 in combination with bortezomib/immunomodulators plus dexamethasone/prednisone in patients with MM.